tbuckley/cabot-search huggingface dataset:
Reincarnate Me
Authors: Noelle M. Northcutt
Journal: Annals of Internal Medicine (2013)

Ad LibitumOctober 1, 2013Reincarnate MeNoelle M. Northcutt, MDNoelle M. Northcutt, MDFrom Aurora, Colorado.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-159-7-201310010-00014 Audio Reading - “Reincarnate Me” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Reincarnate Me," by N.M. Northcutt. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I took one of those slow, deep breaths:“If I die and come back as something better,I hope I will be a seven-year-old girlThat loves science and never stops reading”I did not think that thought hardly.Though it came out strong and surely, surprised me,in fact, so much that even seconds laterI already started recollecting!Though my time to ... Author, Article, and Disclosure InformationAffiliations: From Aurora, Colorado.Current Author Address: Noelle M. Northcutt, MD;e-mail, [email protected]. PreviousarticleNextarticle Advertisement Audio Reading - “Reincarnate Me” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Reincarnate Me," by N.M. Northcutt. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics October 1, 2013Volume 159, Issue 7Page: 499KeywordsGamesSleep ePublished: 1 October 2013 Issue Published: October 1, 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Correction: Hypercalcaemia in malignancy
Journal: BMJ (1989)

since transurethral resection two weeks before.Is this appreciable reduction in morbidity?Certainly he did not have to stay long in hospital, but who is to say that the current operative technique is more agreeable than open prostatectomy-it is done by the same surgeons, registrars, and house officers with intact prostates, who assert that retrograde ejaculation elicits the same sensation as normal.And did one of them consider asking me whether I wanted another child before thev rendered mv husband infertile?Nomy consent was never sought.He was on the
CORONARY PLAQUE COMPONENTS ASSESSED BY VIRTUAL HISTOLOGY-INTRAVASCULAR ULTRASOUND ARE NOT ASSOCIATED WITH NEOINTIMAL HYPERPLASIA IN PATIENTS WHO UNDERWENT DRUG-ELUTING STENT IMPLANTATION
Authors: Young Joon Hong, Myung Ho Jeong, Yun Ha Choi, Eun Hye Ma, Jum Suk Ko, Min Goo Lee, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Youn, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang
Journal: Journal of the American College of Cardiology (2010)
Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).
Authors: Erika Martinelli, Teresa Troiani, Filippo Venturini, Andres Cervantes, Jean-Yves Douillard, Alfredo Falcone, Gunnar Folprecht, Claus-Henning Kohne, Julien Taieb, Josep Tabernero, Claudia Cardone, Vincenzo Sforza, Giulia Martini, Stefania Napolitano, Annalisa Capuano, Fabiana Auricchio, Fortunato Ciardiello
Journal: Journal of Clinical Oncology (2015)

TPS3634 Background: Treatment of metastatic colorectal cancer (mCRC) has improved due to the introduction of more active chemotherapies (CT) and novel targeted agents that have significantly increased response rate (RR), progression free survival (PFS) and overall survival (OS). Recently, CORRECT and CONCUR trials have demonstrated both activity and efficacy of regorafenib, a small multi-kinase inhibitor, as monotherapy in pretreated mCRC. The wide range of action of regorafenib makes it an ideal candidate for monotherapy in earlier disease treatment lines in which different pathways could be involved in the acquisition of resistance. To improve long term efficacy of first line therapy several therapeutic approaches of maintenance treatment have been explored in mCRC. Methods: RAVELLO is an academic randomized, double-blind, placebo-controlled, multi-center, phase III study designed to evaluate efficacy and safety of regorafenib as maintenance treatment after first line therapy. Eligible patients: pathologically confirmed mCRC RAS wild type (KRAS and NRAS genes) treated with a first line fluoropyrimidine-based CT in combination with an anti-EGFR (epidermal growth factor receptor) monoclonal antibody for a minimum of 4 to a maximum of 8 months, with a stratification by response to the first line treatment (complete response/partial response or stable disease). 480 patients will be enrolled and randomly assigned in a 1:1 ratio to receive 160 mg regorafenib or placebo per os, every day for 3 weeks of every 4 weeks cycle, until disease progression or unacceptable toxicity. Primary endpoint is PFS. With a two-tailed alpha error of 0.05, the study will have 90% power to detect a 3-month prolongation of median PFS from randomization (corresponding to a hazard ratio of progression of 0.67 with 6-month median PFS expected in the control arm). Secondary endopoint are OS, safety, and biomarker correlative studies. Currently, one patient has been enrolled and is on treatment. EudraCT number: 2013-005428-41. Clinical trial information: 2013-005428-41.
A Day in the Life of a Corporate Retail Pharmacist
Authors: David D. Dore
Journal: Annals of Internal Medicine (2014)

Letters7 January 2014A Day in the Life of a Corporate Retail PharmacistDavid D. Dore, PharmD, PhDDavid D. Dore, PharmD, PhDFrom Brown University School of Public Health, Providence, Rhode Island.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5000-1 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:I would like to thank Dr. Brock for noting that there are pharmacies where patient care is excellent. I did not intend to impeach these pharmacies, or pharmacists in general, in my characterization of the “typical” day in a corporate retail pharmacy. Rather, these pharmacies should stand as a model for the rest of the profession. My criticism was of the severalfold more prevalent chain pharmacies, which fill approximately 70% of all prescriptions in the United States (1).The system of pharmacy—which, like other health care systems, provides a complex milieu—particularly deserves scrutiny. Early in my training, I ...References1. National Association of Chain Drug Stores. 2011–2012 Chain Pharmacy Industry Profile. Alexandria, VA: National Assoc Chain Drug Stores; 2011. Google Scholar2. O'Connor GT. Every system is designed to get the results it gets [Editorial]. BMJ. 1997;315:897-8. [PMID: 9361535] CrossrefMedlineGoogle Scholar3. Donabedian A. Explorations in Quality Assessment and Monitoring: The Definition of Quality and Approaches to Its Assessment. Ann Arbor: Health Administration Pr; 1980. Google Scholar4. Brown CM, Cantu R, Corbell Z, Roberts K. Attitudes and interests of pharmacists regarding independent pharmacy ownership. J Am Pharm Assoc (2003). 2007;47:174-80. [PMID: 17510004] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Brown University School of Public Health, Providence, Rhode Island.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-1922. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Day in the Life of a Corporate Retail Pharmacist Tina Penick Brock A Day in the Life of a Corporate Retail Pharmacist Tina Penick Brock Metrics Cited byLooking Back at US Pharmacy’s Past to Help Discern Its Future 7 January 2014Volume 160, Issue 1Page: 70KeywordsComplex systemsDisclosureHealth careHealth care qualityLife expectancyMotivationPatientsPharmacistsPrevention, policy, and public healthQuality improvement ePublished: 7 January 2014 Issue Published: 7 January 2014 PDF downloadLoading ...
T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma.
Authors: J C Virchow, C Walker, D Hafner, C Kortsik, P Werner, H Matthys, C Kroegel
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Increasing evidence suggests a role for activated T cells and cytokines in the regulation of eosinophilic inflammation in asthma. In this study, we investigated the distribution of leukocytes, lymphocytes, their activation state, and the cytokine profile in BAL from 10 atopic asthmatics with positive skin prick tests and elevated specific IgE levels to birch or grass pollen. Using segmental allergen challenge, 250 PNU of the appropriate allergen or saline were instilled into different segments, which were lavaged 10 min (10 min) and 18 h (18 h) after allergen challenge or 18 h after saline challenge (C). In peripheral blood the number of neutrophils and activated IL-2R+/CD4+ T cells increased significantly 18 h after allergen provocation; there was no change in eosinophils, other leukocytes, or lymphocyte subsets. In contrast, numbers of eosinophils, neutrophils, and IL-2R+/CD4+ T cells increased significantly in BAL samples at 18 h. The numbers of neutrophils and eosinophils were not significantly different in the lavage performed at 10 min and at C. Analysis of cytokines in concentrated BAL fluid revealed significantly increased levels of IL-5, IL-2, IL-1, TNF-alpha, IL-6, IL-8, and GM-CSF, but not of IL-4 and IFN-gamma at 18 h compared with those at C and at 10 min. The correlation between IL-5 levels, eosinophil numbers, and activated T cells supports a role for T-cell-derived IL-5 in causing tissue eosinophilia in allergic asthma.
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.
Authors: Daniel Vilarim Araujo, Connor Wells, Aaron Richard Hansen, Nazli Dizman, Sumanta K. Pal, Benoit Beuselinck, Frede Donskov, Chun Loo Gan, Flora Yan, Ben Tran, Christian K. Kollmannsberger, Guillermo de Velasco, Takeshi Yuasa, M. Neil Reaume, D. Scott Ernst, Thomas Powles, Georg A. Bjarnason, Toni K. Choueiri, Daniel Yick Chin Heng, Shaan Dudani
Journal: Journal of Clinical Oncology (2020)

5068 Background: Anti-PD-1/PD-L1 immune-checkpoint inhibitors (ICI) are now a standard of care in metastatic renal cell carcinoma (mRCC). Older adults were underrepresented in registration trials and given that immunological senescence may affect the anti-tumor activity of ICIs, there is uncertainty about the efficacy of ICIs in this population. Here we provide real world data on outcomes of older adults with mRCC treated with ICIs. Methods: Patients with mRCC treated with a PD-1/PD-L1 ICI either as monotherapy or as a combination treatment from 2000 to 2019 were included. Older adult was defined as ≥ 70-years at the time of ICI treatment. Descriptive statistics were summarized in means, medians and proportions. Efficacy was assessed by survival analysis, including overall survival (OS), time to treatment failure (TTF), and overall response rate (ORR). Multivariate analyses adjusted for imbalances in IMDC risk factors. P &lt; 0.05 was considered statistically significant. Results: Of 1427 patients, 397 (28%) were older adults. Mean age of older vs. younger adults was 74 (70-92) vs. 60 (22-69) years. Groups were comparable in terms of gender (Female 28.5% vs. 26.1%, p = 0.36), rates of nephrectomy (21% vs. 18.3%, p = 0.24) and presence of sarcomatoid features (12.3% vs. 17.8%, p = 0.14). Proportion of IMDC risk-groups between older vs. younger adults were as follows: 15.4% vs. 18.2% for favorable, 61.2% vs. 59.1% for intermediate, and 23.4% vs. 22.7% for poor; there was no statistical difference (p = 0.55). ICI was used as 1st line in 40%, 2nd line in 48.5% and 3rd line in 11.5% patients; older adults were less likely to be treated with ICI in 1st line (32.2% vs. 43%, p &lt; 0.01). In terms of survival, older adults had poorer median OS (25.1m vs. 30.8m, p &lt; 0.01) but similar median TTF (6.9m vs. 6.9m, p = 0.40) compared to younger adults. In multivariate analyses, older age was not a predictor of either worse OS (aHR = 1.02, p = 0.86) or TTF (aHR = 0.95, p = 0.59). Older adults had a lower ORR compared to younger (24% vs. 31%, p = 0.01), which was mainly driven by responses in 1st line (31% vs. 44%, p = 0.02) and not observed in 2nd/3rd line (20% vs. 20%, p = 0.86). Conclusions: On multivariate analyses, older adults with mRCC treated with ICI had no difference in OS and TTF when compared to younger adults, despite having lower ORR in 1st line. Our data supports that older age is not an independent risk factor for survival; thus, treatment selection should not be based solely on chronological age.
Medical Education
Authors: John P. Callan
Journal: JAMA (1979)

It seems an ironic and troubling commentary on our times that the majority of physicians know so much about medicine and so little about arenas outside the healing arts. Like prevoyage Columbus they may have a suspicion that there is more beyond the boundaries of scientific medicine, yet few physicians possess the drive and purpose to stray from the scientific and narrow path into broader areas. Not all the blame for this can be placed at the doors of present-day practitioners; part must be directed toward our standard method of producing physicians—our singularly minded educational system with its obsessions on scientific didacticism. Throughout college and medical school, emphasis is placed on acquiring and memorizing fact on fact until it seems the world is made up of medical minutiae and nothing else. Art, the humanities, the classics, philosophy, and other studies that might detract from learning the insertion and action of
ABSORPTION OF SURGICAL GUT
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Maternal Rubella
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Tropical Nursing: A handbook for nurses and others going abroad . By A. L. Gregg, M.A., M.D., M.Ch., B.A.O. (Dublin), D.T.M. &amp; H. (Lond.), L.M. (Rotunda Hospital). Second edition. 16°, cloth, 185 pp. New York: Philosophical Library, 1944. $3.00.
Journal: New England Journal of Medicine (1944)
Gastroesophageal Reflux
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immune Function Assays As Indicators of Chromate Exposure
Authors: Carroll A. Snyder, Celeste D. Valle
Journal: Environmental Health Perspectives (1991)

The potential immunomodulatory effects of chromium were investigated using a series of in vitro and in vivo studies. Chromium (as K2CrO4) in concentrations spanning five orders of magnitude was added in vitro to T-lymphocyte (concanavalin A) and B-lymphocyte (liposaccharide) mitogen cultures and was found to inhibit T-lymphocyte responses at all concentrations tested and to inhibit B-lymphocyte responses at all but the lowest concentration tested (0.01 mg/L). When the same concentrations of chromium were employed in mixed lymphocyte cultures, antigen-induced thymidine uptake was inhibited at the highest concentrations (100 mg/L-1 mg/L), enhanced at 0.1 mg/L, and equal to control values at lower concentrations. Splenocytes isolated from rats exposed to K2CrO4 in drinking water exhibited enhanced responses to T- and B-lymphocyte mitogens. The addition of 0.1 mg/L of chromium to a mixed lymphocyte culture containing splenocytes taken from chromium-exposed rats increased by 5-fold the uptake of thymidine by these cells. These increased responses of cells from chromium-exposed rats may indicate chromium-induced sensitization and may possibly be used as a biological marker for chromium exposure.
The Relative Intelligibility of Esophageal Speech and Artificial
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Panton &amp;amp; Marrack's Clinical Pathology
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extracranial arterial occlusion as a cause of stroke. A cooperative study
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal